Change of legal form

Biotest AG now operates under the name Biotest GmbH & Co. KGaA

Careers

Careers

Passionate to help us save lives?

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation / Yimmugo (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation / Yimmugo (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen / Prufibry / Fesilty (BT524) - Congenital fibrinogen deficiency
Fibrinogen / Prufibry / Fesilty (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia

Pipeline

Pipeline

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.